First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants

First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants

BMS-986141 is a novel, oral, protease-activated, receptor 4 (PAR4)-antagonist that exhibited robust antithrombotic activity and low bleeding risk in preclinical studies. The pharmacokinetic, pharmacodynamic, and tolerability profiles of BMS-986141 in healthy participants were assessed in a randomize...

Full description

Bibliographic Details
Main Authors: Samira Merali, Zhaoqing Wang, Charles Frost, Stephanie Meadows-Shropshire, Dara Hawthorne, Jing Yang, Dietmar Seiffert
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Platelets
Subjects:
antiplatelet
antithrombotic therapy
clinical trial
par4
pharmacokinetics
platelet
protease-activated receptor
Online Access:http://dx.doi.org/10.1080/09537104.2023.2222846

Internet

http://dx.doi.org/10.1080/09537104.2023.2222846

Similar Items